Experience Matters
Providing expert advice in health economics, pricing & reimbursement, market access and regulatory affairs in Australia.
Welcome to Lucid Health Consulting
With over 30 years of Health Economics, Pricing & Reimbursement, Strategic Market Access and Health Technology Assessment experience, we have helped many organisations navigate the complexities of the Australian regulatory environment and achieve market access.
We have a proven track record of enabling companies and organisations to optimise the entry of their pharmaceutical, biotech and medical devices into the Australian market.
Let us show you how our strategic approach and team experience can help you achieve market access in Australia.
How we can help your business?
What’s New
Read our articles, find out about our upcoming webinars and speaking engagements for the latest industry insights.
Lucid Health Consulting joint publication – Journal of Medical Economics.
Read our Director George Papadopoulos’s recently published joint manuscript, in the Journal of Medical Economics; Cost-effectiveness analysis of arthroscopic injection of a bioadhesive hydrogel implant in conjunction with microfracture for the treatment of focal...
ISPOR HTA Innovations Workshop, 13th July 2022
At Lucid Health Consulting we are delighted to be a proud sponsor for ISPOR’s upcoming HTA Innovations Workshop. The HTA workshop will be held in-person on 13 July, from 10:00 am - 4:00 pm AEST, at the Aerial UTS Function Centre, Ultimo, Sydney. With the announcement...
ISPOR 2022 Global Conference – Lucid Health Consulting Poster
Lucid Health Consulting ISPOR 2022 Poster titled: “Cost-Effectiveness Analysis of Arthroscopic Injection of a Bioadhesive Hydrogel Implant in Conjunction with Microfracture for the Treatment of Focal Chondral Defects of the Knee: An Australian Perspective.” At...
What our clients are saying.
Lucid Health Consulting are providers of expert advice in health economics, pricing & reimbursement, market access and regulatory affairs in Australia. Enabling companies to optimise the entry of their pharmaceutical, biotech and medical devices into the Australian market.